Adult growth hormone deficiency
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: (1) Patients with AGHD requiring Somapacitan therapy (2) Patients who are 20 years of age or older at the time of obtaining consent (3) Patients who have been fully informed about their participation in this study, and who have given written consent of their own free will based on their full understanding of the study.
Exclusion criteria
Exclusion criteria: (1) Patients with contraindications to Somapacitan (2) Other subjects deemed inappropriate as research subjects by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Athens Insomnia Scale score before and after starting or changing Somapacitan | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Change in SF-36 score before and after starting or changing Somapacitan 2) Change in blood examination before and after starting or changing Somapacitan 3) Change in body composition before and after starting or changing Somapacitan 4) Adverse events during the observation period | — |
Countries
Japan
Contacts
Department of Internal Medicine, Faculty of Internal Medicine, University of Miyazaki Division of Hematology, Diabetes, and Endocrinology